Abstract
Combination therapies that activate the mevalonate pathway in GBM cells after sublethal treatment enhance self-renewal and migratory capacity through Rac-1 activation, which creates a metabolic vulnerability that can be further potentially exploited using statins.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have